⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SPRO News
Spero Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
SPRO
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
globenewswire.com
SPRO
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SPRO
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
globenewswire.com
SPRO
International Avocado Day: Innovative Certification Program Covers More Than 90% of Mexican Avocados Exported to US
prnewswire.com
FDP
COST
SPRO
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
globenewswire.com
SPRO
Form 8-K
sec.gov
SPRO
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
globenewswire.com
SPRO
KKR